Navigation Links
Wyeth Initiates INTORACT -- A New Clinical Trial to Examine TORISEL Plus Avastin for First-Line Treatment of Advanced Kidney Cancer
Date:5/30/2008

such statements. These risks and uncertainties include, without limitation, the inherent uncertainty of the timing and success of, and expense associated with, research, development, regulatory approval and commercialization of our products and pipeline products; government cost- containment initiatives; restrictions on third-party payments for our products; substantial competition in our industry, including from branded and generic products; emerging data on our products and pipeline products; the importance of strong performance from our principal products and our anticipated new product introductions; the highly regulated nature of our business; product liability, intellectual property and other litigation risks and environmental liabilities; uncertainty regarding our intellectual property rights and those of others; difficulties associated with, and regulatory compliance with respect to, manufacturing of our products; risks associated with our strategic relationships; economic conditions including interest and currency exchange rate fluctuations; changes in generally accepted accounting principles; trade buying patterns; the impact of legislation and regulatory compliance; risks and uncertainties associated with global operations and sales; and other risks and uncertainties, including those detailed from time to time in our periodic reports filed with the Securities and Exchange Commission, including our current reports on Form 8-K, quarterly reports on Form 10-Q and annual report on Form 10-K, particularly the discussion under the caption "Item 1A, Risk Factors" in our Annual Report on Form 10-K for the year ended December 31, 2007, which was filed with the Securities and Exchange Commission on February 29, 2008. The forward-looking statements in this press release are qualified by these risk factors. We assume no obligation to publicly update any forward-looking statements, whether as a result of new information, future developments or otherwise.

Note
'/>"/>

SOURCE Wyeth Pharmaceuticals
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Wyeth Receives Approvable Letter from FDA for TYGACIL for the Treatment of Patients with Community-Acquired Pneumonia
2. Wyeth Receives FDA Fast Track Designation for its 13-valent Pneumococcal Conjugate Vaccine for Infants and Toddlers
3. Wyeth Receives Approvable Letter From FDA for Bazedoxifene for the Treatment of Postmenopausal Osteoporosis
4. Wyeth and Progenics Announce Preliminary Clinical Trial Results for RELISTOR Oral and Intravenous Formulations
5. Arthritis Foundation Announces Amgen and Wyeth to Be Presenting Sponsor of the 2008 Arthritis Walk (R)
6. Wyeths TORISEL Receives European Commission Approval for the Treatment of Advanced Kidney Cancer
7. FDA Accepts Wyeths Supplemental New Drug Application for Tygacil for the Treatment of Patients with Community-Acquired Pneumonia
8. Wyeth Presents New Phase 3 Data and Updates Regulatory Timing for NDA Filing of Bazedoxifene/Conjugated Estrogens
9. Wyeth Presents Phase 3 Fracture Data for Bazedoxifene, an Investigational Therapy for Osteoporosis
10. Wyeths Torisel and Roche/Genentechs Avastin Will Challenge Pfizers Sutent to Become the Clinical Gold Standard for Treatment of Metastatic Renal Cell Carcinoma
11. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... 29, 2014 China Biologic Products, Inc. (NASDAQ: ... integrated plasma-based biopharmaceutical company in China ... second quarter 2014 financial results on Tuesday, August 5, ... Company,s management will hold a conference call at 8:00 ... 8:00 p.m., Beijing Time on August 6, 2014, to ...
(Date:7/29/2014)... , July 29, 2014 , ... /Oxymorphone clinical development program has commenced , ... Australia during Q4 2014 , ... States in 1H 2015 Australian drug ... on its opioid transdermal patch programs after its recent announcement of ...
(Date:7/29/2014)... ROCKLAND, Massachusetts , July 29, 2014 ... an international Phase II study investigating the efficacy and safety ... mMCC is a rare and aggressive skin cancer ... explored in a seven cohort Phase I clinical trial for ... patients  , EMD Serono, Inc., a subsidiary of ...
Breaking Medicine Technology:China Biologic to Report Second Quarter 2014 Financial Results 2China Biologic to Report Second Quarter 2014 Financial Results 3Phosphagenics Provides Update on Opioid Patch Program 2Phosphagenics Provides Update on Opioid Patch Program 3Phosphagenics Provides Update on Opioid Patch Program 4Phosphagenics Provides Update on Opioid Patch Program 5Phosphagenics Provides Update on Opioid Patch Program 6EMD Serono Initiates Phase II Study of Anti-PD-L1 Antibody MSB0010718C in Metastatic Merkel Cell Carcinoma 2EMD Serono Initiates Phase II Study of Anti-PD-L1 Antibody MSB0010718C in Metastatic Merkel Cell Carcinoma 3EMD Serono Initiates Phase II Study of Anti-PD-L1 Antibody MSB0010718C in Metastatic Merkel Cell Carcinoma 4EMD Serono Initiates Phase II Study of Anti-PD-L1 Antibody MSB0010718C in Metastatic Merkel Cell Carcinoma 5
... First Extensive Report of Bile Acid Aberration in Type 2 Diabetes ... ... N.J., June 9 /PRNewswire-FirstCall/,-- KineMed, Inc., and Daiichi Sankyo, Inc., announced ... people with type 2,diabetes which may suggest a newly identified underlying ...
... 9 Pharmacyclics, Inc.,(Nasdaq: PCYC ) today ... orally available, selective inhibitor of Bruton,s tyrosine,kinase, or ... model,for rheumatoid arthritis (RA). The data were presented ... being held this,week in Boston, MA., Researchers ...
Cached Medicine Technology:New Discovery of Key Difference in Bile Acid Metabolism in Patients with Type 2 Diabetes May Suggest Underlying Disorder 2New Discovery of Key Difference in Bile Acid Metabolism in Patients with Type 2 Diabetes May Suggest Underlying Disorder 3New Discovery of Key Difference in Bile Acid Metabolism in Patients with Type 2 Diabetes May Suggest Underlying Disorder 4New Discovery of Key Difference in Bile Acid Metabolism in Patients with Type 2 Diabetes May Suggest Underlying Disorder 5New Discovery of Key Difference in Bile Acid Metabolism in Patients with Type 2 Diabetes May Suggest Underlying Disorder 6New Discovery of Key Difference in Bile Acid Metabolism in Patients with Type 2 Diabetes May Suggest Underlying Disorder 7Pharmacyclics Novel Btk Inhibitor Shows Efficacy in Preclinical Models of Rheumatoid Arthritis and Lymphoma 2Pharmacyclics Novel Btk Inhibitor Shows Efficacy in Preclinical Models of Rheumatoid Arthritis and Lymphoma 3Pharmacyclics Novel Btk Inhibitor Shows Efficacy in Preclinical Models of Rheumatoid Arthritis and Lymphoma 4
(Date:7/29/2014)... According to an article in the Daily ... a 52 year old woman in India. The surgery took ... had no idea that she had such a large tumor ... for years, but did not connect it to a possible ... the massive uterine fibroid after Latha was admitted for heavy ...
(Date:7/29/2014)... Little Rock, AR (PRWEB) July 29, 2014 ... S.Res.518 , a resolution declaring the week of October ... the value of case management in improving healthcare outcomes ... Pryor (D-AR) and Senator John Boozman (R-AR), with support ... American Case Management Association to honor case management professionals ...
(Date:7/29/2014)... Bethesda, Maryland (PRWEB) July 29, 2014 ... has been named a 2014 ASAE Power of ... Flu-Focused," a public awareness campaign to encourage everyone age ... annually. , ASAE recognized NFID for its power ... drive awareness and action among consumers and professionals about ...
(Date:7/29/2014)... Award-winning inventor Michael Croix has launched an Indiegogo campaign for ... embarrassing odors in the office. PoofPad is a discrete bag ... desk drawer. This compact packaging is designed for ease of ... the pad and poof away! , “We’ve all been there. ... appears out of nowhere. It’s embarrassing and unpleasant for everyone ...
(Date:7/29/2014)... Recognition, and Control (A.R.C.) Against Depression" was written by ... men to heed the call to self-help.. , Ray J. ... no job, leaving Raymond with a mortgage payment he could ... the emotional disturbance was so great that they put him ... to the root of his problems. , Raynond says, “Even ...
Breaking Medicine News(10 mins):Health News:World’s Largest Uterine Fibroid Removed from Patient 2Health News:World’s Largest Uterine Fibroid Removed from Patient 3Health News:CMSA Supports National Case Management Week Resolution Introduced in US Senate 2Health News:National Foundation for Infectious Diseases Receives Top ASAE Honors for Keeping the Nation Flu-Focused 2Health News:Award-Winning Inventor Michael Croix Launches an Indiegogo Campaign for PoofPad 2Health News:Award-Winning Inventor Michael Croix Launches an Indiegogo Campaign for PoofPad 3Health News:SBPRA Announces the Release of Its Newest Title, "Acceptance, Recognition, and Control (A.R.C.) Against Depression" 2
... HIV-positive head and neck cancer patients respond well to ... non-HIV-positive patients, despite prior reports to the contrary, according ... International Journal of Radiation OncologyBiologyPhysics , an official ... , Patients with HIV have a significantly higher risk ...
... A new program designed to create comprehensive, integrated, whole-person ... a $3.9 million grant from the Colorado Health Foundation. ... in the Department of Family Medicine at the University of ... and national leaders from the mental health, substance use, and ...
... , TUESDAY, Jan. 18 (HealthDay News) -- Seeing ... smokers, brains to plan the same motions, new research shows. ... brain activity in 17 smokers and 17 nonsmokers as they ... scenes, the smokers, brains showed increased activity in areas involved ...
... TORONTO, ON Adult children of divorce are more likely to ... suggests new research from the University of Toronto , In ... Psychiatry Research, investigators examined gender specific differences among a ... divorce before the age of 18. The study found that ...
... By Jenifer Goodwin HealthDay Reporter , ... reports from patients suggest that a controversial treatment for ... but many physicians remain highly skeptical of the ... Paolo Zamboni, a vascular surgeon from Italy, published an ...
... Rochester Institute of Technology indicates that the incidence of ... more than 25 percent higher among deaf and hard-of-hearing ... a direct correlation between childhood maltreatment and higher rates ... The study, which was presented at the 2010 ...
Cached Medicine News:Health News:HIV-positive head and neck cancer patients benefit from radiation therapy 2Health News:New program targeting whole-person health care gets major grant 2Health News:Smoking Scenes in Movies Light Up Smokers' Brains 2Health News:Parental divorce linked to suicidal thoughts 2Health News:Vein-Opening Treatment for MS Stirs Controversy 2Health News:Vein-Opening Treatment for MS Stirs Controversy 3Health News:Vein-Opening Treatment for MS Stirs Controversy 4Health News:Study: Abuse rates higher among deaf and hard-of-hearing children compared with hearing youths 2
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: